IDEAYA Biosciences, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

IDEAYA Biosciences reported a quarterly adjusted loss of $1.22 per share, wider than the $1.18 loss fifteen analysts expected. Revenue fell 95.1% to $10.24 million, above the $6.86 million analysts expected. The company posted a quarterly loss of $128.96 million.

Confirmed

Global impact / market context

A 95.1% revenue drop leaves little cash coming in to fund drug research, which is costly and slow. The wider-than-expected loss adds pressure to control spending or raise money, and the stock's 17.6% quarterly fall shows investors already price in concern.

Analyst inference

Analysts still rate the shares a buy on average, with a median 12-month price target of $51.00, about 38% above the $31.64 last close. That gap suggests the buy case rests on future drug results, not current sales, so earnings misses can hit the stock hard.

Analyst inference

What to watch

1. Watch whether revenue stays near $10.24 million next quarter, since a 95.1% yearly drop leaves little recurring income to fund research. Confirmed
2. Watch for company plans to raise cash or cut research spending, because a $128.96 million quarterly loss may require new funding. Proposed
3. Watch whether the $51.00 median price target holds after the earnings miss, since analyst confidence could weaken and shift the stock. Analyst inference

Evidence

• Original source link unavailable